US-based Chembio Diagnostics has partnered with LumiraDx for the development of point-of-care (POC) diagnostic tests to detect infectious diseases.

As per the collaboration, LumiraDx will provide funding to Chembio, upon achievement of select milestones, to develop the new tests.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Chembio is set to leverage its DPP technology platform that is said to provide significant advantages compared to standard POC lateral-flow technologies.

In addition, the technology offers possibilities in sexually transmitted disease, tropical and fever disease areas, along with opportunities for technology partnerships.

“Under the terms of the agreement, the regulatory approval, commercialisation and sales of the tests resulting from the alliance will fetch royalty payments from LumiraDx to Chembio.”

Chembio Diagnostics CEO John Sperzel said: “We are excited about the collaboration with LumiraDx as it validates our scientific expertise and complements our DPP platform strategy.

“Through our joint efforts, we expect the new products to provide access to a broader customer base.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

“In addition, we anticipate expanding our product portfolio by applying reagent biomarkers funded through this agreement to our DPP platform.”

Under the terms of the agreement, the regulatory approval, commercialisation and sales of the tests resulting from the alliance will fetch royalty payments from LumiraDx to Chembio.

Furthermore, Chembio will sell reagents to LumiraDx.

LumiraDx chairman and CEO Ron Zwanziger said: “We selected Chembio as our partner due to the company’s expertise in developing high-quality POC infectious disease assays, and we believe the commercial opportunity for both firms is significant.”

In December last year, Chembio formed a similar partnership with AstraZeneca to develop a new quantitative reader-based POC diagnostic test to identify an undisclosed biomarker. The 18-month agreement involved an up to $2.9m grant from AstraZeneca.